Govt approves Umang Vohra as Chairman and Group CEO of Cohance

Ceo Appointed ExternalManagement Changes View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹445.65

prior close

₹447.50

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.3%-2.5% vs market

Pharmaceuticals peers, median of 168sector-0.3%-1.8% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Smallcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-1.8

15m

-1.8

30m

-2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2+0.3-2.5-0.3-1.8

Next day

+0.5+0.3+0.1-0.3+0.8

+3.3-0.8+4.1-1.2+4.5

+4.3-0.8+5.0-1.0+5.3

+2.4-1.9+4.3-2.6+5.0

+3.5-4.1+7.7-4.0+7.6

+1.4-7.8+9.2-6.5+8.0

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences says the Ministry of Corporate Affairs has approved Mr Umang Vohra as Chairman and Group CEO of the company. The approval came via a letter dated 8 October 2026 and was received by the company on 12 October 2026. This follows earlier intimation letters from April and June 2026 about his appointment, with the final regulatory clearance now secured.

Likely market impact

Final regulatory approval secured for Chairman and Group CEO role, removing uncertainty around top leadership at Cohance Lifesciences.